Serina Therapeutics, Inc. (SER) compared with its closest peers (ANVS, TELO, IBIO, PLRX, RNTX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Annovis Bio, Inc. (ANVS) | $77.12M | -2.5 |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $77.03M | -4.0 |
| iBio, Inc. (IBIO) | $71.54M | -0.4 |
| Pliant Therapeutics, Inc. (PLRX) | $71.52M | -0.5 |
| Rein Therapeutics Inc. (RNTX) | $71.52M | -0.6 |
| Spero Therapeutics, Inc. (SPRO) | $70.93M | 9.6 |
| PMV Pharmaceuticals, Inc. (PMVP) | $70.56M | -0.9 |
| XBiotech Inc. (XBIT) | $69.82M | -1.6 |
| OS Therapies Incorporated (OSTX) | $69.19M | -1.4 |
| MediciNova, Inc. (MNOV) | $68.66M | -5.4 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
SER overview · SER earnings · SER financials · SER KPIs · SER investor relations · SER ownership · SER filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.